Anthony J Hatswell

List of Publications by Year
in descending order

42 papers	681 citations	623734 14 h-index	610901 24 g-index
42 all docs	42 docs citations	42 times ranked	1073 citing authors

#	Article	IF	Citations
1	Approaches to Selecting "Time Zero" in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches. Medical Decision Making, 2022, 42, 893-905.	2.4	3
2	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood, 2022, 140, 851-860.	1.4	28
3	Carers' Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations. Pharmacoeconomics, 2022, 40, 837-850.	3.3	11
4	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. Applied Health Economics and Health Policy, 2021, 19, 389-401.	2.1	3
5	A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). Blood, 2021, 138, 3543-3543.	1.4	5
6	Creating historical controls using data from a previous line of treatment â€" Two non-standard approaches. Statistical Methods in Medical Research, 2020, 29, 1563-1572.	1.5	8
7	Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data. PharmacoEconomics - Open, 2020, 4, 133-142.	1.8	11
8	Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clinical Trials, 2020, 17, 607-616.	1.6	18
9	Real-world evidence use in assessments of cancer drugs by NICE. International Journal of Technology Assessment in Health Care, 2020, 36, 388-394.	0.5	23
10	The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study. Value in Health, 2020, 23, 751-759.	0.3	11
11	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 2020, 20, 103.	3.1	10
12	Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic. PharmacoEconomics - Open, 2020, 4, 203-205.	1.8	13
13	The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer. Health Economics Review, 2020, 10, 10.	2.0	1
14	NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence. Pharmacoeconomics, 2019, 37, 1383-1390.	3.3	11
15	Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health and Quality of Life Outcomes, 2019, 17, 171.	2.4	6
16	PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study. Journal of Hepatology, 2019, 70, e35-e36.	3.7	0
17	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics - Open, 2019, 3, 377-390.	1.8	20
18	Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 2019, 19, 20.	3.1	8

#	Article	IF	Citations
19	Transparency in Decision Modelling: What, Why, Who and How?. Pharmacoeconomics, 2019, 37, 1355-1369.	3.3	28
20	Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes. Applied Health Economics and Health Policy, 2019, 17, 391-397.	2.1	14
21	Frequentist and <scp>B</scp>ayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Economics (United) Tj ETQq1 1 0.784314 rgBT3Overlo	1.8	13
22	The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation. PharmacoEconomics - Open, 2018, 2, 241-253.	1.8	5
23	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics, 2018, 21, 666-675.	2.1	36
24	Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. Clinical Colorectal Cancer, 2018, 17, e143-e151.	2.3	24
25	Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). Annals of Oncology, 2018, 29, viii461.	1.2	0
26	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. Pharmacoeconomics, 2018, 36, 1421-1426.	3.3	63
27	Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: An economic impact analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 210, 286-291.	1.1	29
28	Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling. Pharmacoeconomics, 2017, 35, 755-757.	3.3	6
29	Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia. Cost Effectiveness and Resource Allocation, 2017, 15, 8.	1.5	13
30	Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Journal of Medical Economics, 2017, 20, 193-199.	2.1	15
31	Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy. Pharmacoeconomics, 2017, 35, 163-176.	3.3	9
32	How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation. Ecancermedicalscience, 2017, 11, ed67.	1.1	1
33	New Cancer Drugs Fund solves the wrong problem. BMJ, The, 2016, 355, i5619.	6.0	0
34	The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma. Clinical Therapeutics, 2016, 38, 503-515.	2.5	9
35	The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health, 2016, 19, 1055-1058.	0.3	4
36	Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open, 2016, 6, e011666.	1.9	126

#	Article	IF	Citations
37	Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3ÂL and PAC-QOL. Health Economics Review, 2016, 6, 14.	2.0	13
38	Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK. Pharmacoeconomics, 2016, 34, 1145-1159.	3.3	17
39	Survival outcomes and treatment costs for patients with doubleâ€refractory chronic lymphocytic leukaemia (<scp>DR</scp>â€<scp>CLL</scp>). British Journal of Haematology, 2015, 169, 449-452.	2.5	0
40	The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS ONE, 2015, 10, e0145524.	2.5	16
41	Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 2014, 12, 140.	2.4	38
42	A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe. Health Economics Review, 2014, 4, 6.	2.0	12